Sunmax Biotechnology Co., Ltd.

TPEX:4728 Stock Report

Market Cap: NT$15.0b

Sunmax Biotechnology Past Earnings Performance

Past criteria checks 4/6

Sunmax Biotechnology has been growing earnings at an average annual rate of 35.9%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 22.9% per year. Sunmax Biotechnology's return on equity is 51.1%, and it has net margins of 40.1%.

Key information

35.9%

Earnings growth rate

35.9%

EPS growth rate

Biotechs Industry Growth12.2%
Revenue growth rate22.9%
Return on equity51.1%
Net Margin40.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Investors Who Bought Sunmax Biotechnology (GTSM:4728) Shares Three Years Ago Are Now Up 166%

Feb 28
Investors Who Bought Sunmax Biotechnology (GTSM:4728) Shares Three Years Ago Are Now Up 166%

Is Sunmax Biotechnology Co., Ltd. (GTSM:4728) The Right Choice For A Smart Dividend Investor?

Feb 02
Is Sunmax Biotechnology Co., Ltd. (GTSM:4728) The Right Choice For A Smart Dividend Investor?

Sunmax Biotechnology Co., Ltd.'s (GTSM:4728) Stock Is Going Strong: Is the Market Following Fundamentals?

Dec 20
Sunmax Biotechnology Co., Ltd.'s (GTSM:4728) Stock Is Going Strong: Is the Market Following Fundamentals?

Is Sunmax Biotechnology's (GTSM:4728) Share Price Gain Of 152% Well Earned?

Nov 24
Is Sunmax Biotechnology's (GTSM:4728) Share Price Gain Of 152% Well Earned?

Revenue & Expenses Breakdown

How Sunmax Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:4728 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,74369948333
30 Jun 241,76071248335
31 Mar 241,72467448632
31 Dec 231,68962648129
30 Sep 231,67458249628
30 Jun 231,56453547423
31 Mar 231,46852943720
31 Dec 221,40053440718
30 Sep 221,29250636118
30 Jun 221,18141038920
31 Mar 221,09331642824
31 Dec 211,03624650225
30 Sep 211,08227752021
30 Jun 211,02325449117
31 Mar 211,01629445017
31 Dec 2085623835118
30 Sep 206377032917
30 Jun 2063411030521
31 Mar 205897031021
31 Dec 1959410031723
30 Sep 1958417126625
30 Jun 1947212622823
31 Mar 193629618424
31 Dec 183047515820
30 Sep 182595014016
30 Jun 182294013116
31 Mar 182002812312
31 Dec 171901711212
30 Sep 171892410014
30 Jun 17188248713
31 Mar 1716427717
31 Dec 1615627720
30 Sep 16120-318119
30 Jun 16112-458922
31 Mar 16114-409420
31 Dec 15112-449421
30 Sep 15151-179330
30 Jun 1515108628
31 Mar 15165137926
31 Dec 14184207822
30 Sep 14177257710
30 Jun 1419328799
31 Mar 1421241819

Quality Earnings: 4728 has a high level of non-cash earnings.

Growing Profit Margin: 4728's current net profit margins (40.1%) are higher than last year (34.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4728's earnings have grown significantly by 35.9% per year over the past 5 years.

Accelerating Growth: 4728's earnings growth over the past year (20.2%) is below its 5-year average (35.9% per year).

Earnings vs Industry: 4728 earnings growth over the past year (20.2%) exceeded the Biotechs industry 8.8%.


Return on Equity

High ROE: 4728's Return on Equity (51.1%) is considered outstanding.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 00:20
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sunmax Biotechnology Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Regina LeeJih Sun Securities Investment Consulting Co., Ltd.